Pfg Advisors Eli Lilly & CO Transaction History

Pfg Advisors

$1.35 Billion
Q1 2024

A detailed history of Pfg Advisors transactions in Eli Lilly & CO stock. As of the latest transaction made, Pfg Advisors holds 2,968 shares of LLY stock, worth $2.71 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares

2,968

Previous 2,014 47.37%

Holding current value

$2.71 Million

Previous $1.17 Million 96.59%

% of portfolio

0.17%

Previous 0.1%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	BUY	$592.2 - $792.28 $564,958 - $755,835	954 Added 47.37%	2,968 $2.31 Million
Q4 2023 Jan 19, 2024	SELL	$525.19 - $619.13 $2,100 - $2,476	-4 Reduced 0.2%	2,014 $1.17 Million
Q3 2023 Oct 13, 2023	SELL	$434.7 - $599.3 $1.16 Million - $1.6 Million	-2,678 Reduced 57.03%	2,018 $1.08 Million
Q2 2023 Jul 20, 2023	BUY	$350.74 - $468.98 $539,087 - $720,822	1,537 Added 48.65%	4,696 $2.2 Million
Q1 2023 Apr 20, 2023	BUY	$310.63 - $364.82 $604,485 - $709,939	1,946 Added 160.43%	3,159 $1.08 Million

Q4 2022 Jan 27, 2023	BUY	$321.55 - $374.67 $17,042 - $19,857	53 Added 4.57%	1,213 $443,000
Q3 2022 Oct 13, 2022	SELL	$296.48 - $337.87 $18,974 - $21,623	-64 Reduced 5.23%	1,160 $375,000
Q2 2022 Jul 13, 2022	BUY	$278.73 - $327.27 $36,792 - $43,199	132 Added 12.09%	1,224 $397,000
Q1 2022 Apr 19, 2022	SELL	$234.69 - $291.66 $2,346 - $2,916	-10 Reduced 0.91%	1,092 $313,000
Q3 2021 Nov 05, 2021	SELL	$221.6 - $272.71 $44,320 - $54,541	-200 Reduced 15.36%	1,102 $255,000
Q2 2021 Jul 28, 2021	SELL	$180.55 - $233.54 $3,069 - $3,970	-17 Reduced 1.29%	1,302 $299,000
Q1 2021 Apr 27, 2021	BUY	$164.32 - $212.72 $216,738 - $280,577	1,319 New	1,319 $246,000

Others Institutions Holding LLY

# of Institutions

3,725

Shares Held

738M

Call Options Held

7.09M

Put Options Held

7.24M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $869B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pfg Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Pfg Advisors with notifications on news.

Account